Please assess the completion status of the following clinical trial:

Trial Title: Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* On mechanical ventilator more than 7 days~* VAP diagnosis inclusion criteria:~  1. new/progressive infiltration of chest radiography~ 2. 2/3 of the following: 1) fever 2) purulent sputum 3) Wbc \> 12,000 cell/mm3 or \< 4,000 cell/mm3~* Evidence of gram negative bacilli from sputum gram stain or previous sputum culture within 1 week~Exclusion Criteria:~* History of amikacin allergy~* GFR \< 30 mL/min except dialytic patients~* Immunocompromised host: HIV CD4 \< 200 cells/mm3, leukemia, lymphoma, received chemotherapy within 3 weeks, Absolute neutrophil count \< 500/mm3~* Severe ARDS (P/F ratio \< 100)~* Endobronchial obstruction:endobronchial mass, endobronchial stenosis~* Atelectasis~* Severe bronchospasm~* Lung abscess~* Complicated parapneumonic effusion/ Empyema~* Chest trauma~* Uncontrolled extrapulmonary infection(s)~* Received intravenous antibiotic(s) more than 48 hours~* Pregnancy/ Lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebulized amikacin (Type: EXPERIMENTAL): Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
- placebo (Type: PLACEBO_COMPARATOR): nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).